Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$184.48 USD
+1.74 (0.95%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $184.71 +0.23 (0.12%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Krystal Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 532 | 379 | 438 | 271 | 194 |
Receivables | 42 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 5 | 4 | 4 | 2 |
Total Current Assets | 588 | 384 | 442 | 275 | 196 |
Net Property & Equipment | 161 | 162 | 112 | 31 | 8 |
Investments & Advances | 62 | 5 | 64 | 0 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 2 | 1 |
Total Assets | 818 | 558 | 626 | 311 | 209 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 8 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 27 | 23 | 16 | 5 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 33 | 29 | 26 | 15 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 40 | 36 | 33 | 19 | 6 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,048 | 804 | 735 | 363 | 242 |
Retained Earnings | -270 | -281 | -141 | -71 | -39 |
Other Equity | 1 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 779 | 522 | 594 | 292 | 203 |
Total Liabilities & Shareholder's Equity | 818 | 558 | 626 | 311 | 209 |
Total Common Equity | 779 | 522 | 594 | 292 | 203 |
Shares Outstanding | 28.20 | 25.70 | 22.20 | 19.70 | 17.30 |
Book Value Per Share | 27.61 | 20.32 | 26.74 | 14.83 | 11.73 |
Fiscal Year End for Krystal Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 560 | 538 | 532 | 562 | 478 |
Receivables | 103 | 46 | 42 | 9 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 12 | 11 | 7 | 5 | 0 |
Other Current Assets | 8 | 6 | 7 | 5 | 6 |
Total Current Assets | 683 | 602 | 588 | 582 | 484 |
Net Property & Equipment | 159 | 160 | 161 | 164 | 164 |
Investments & Advances | 69 | 84 | 62 | 37 | 28 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 918 | 853 | 818 | 790 | 684 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 4 | 4 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 65 | 41 | 27 | 22 | 18 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 72 | 48 | 33 | 28 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 79 | 54 | 40 | 34 | 31 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,093 | 1,068 | 1,048 | 1,035 | 1,013 |
Retained Earnings | -253 | -269 | -270 | -279 | -359 |
Other Equity | -1 | 0 | 1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 839 | 799 | 779 | 756 | 653 |
Total Liabilities & Shareholder's Equity | 918 | 853 | 818 | 790 | 684 |
Total Common Equity | 839 | 799 | 779 | 756 | 653 |
Shares Outstanding | 28.70 | 28.50 | 28.20 | 28.20 | 27.90 |
Book Value Per Share | 29.23 | 28.04 | 27.61 | 26.81 | 23.41 |